



# Summary

Summary Type: Reference Pack Summary  
Enhancement

ID Number: 0073137

Date: October 1, 2025



# Disclaimer & Agreement Summary

## Purpose and Scope

This document is an informational summary of medical records prepared by **YourMedReview LLC** (“the Company”) under a fully executed **Terms & Conditions** and **Business Associate Agreement (BAA)** between the Company and the User.

Our engagement is limited to summarizing, organizing, and presenting information contained in the records you provide.

We do **not** render medical, legal, or financial advice, nor do we provide expert opinions or certifications.

---

## Protected Health Information (PHI)

All records have been handled in compliance with the **Health Insurance Portability and Accountability Act (HIPAA)** and the **Health Information Technology for Economic and Clinical Health Act (HITECH)**.

YourMedReview LLC functions as a **HIPAA Business Associate** and maintains administrative, technical, and physical safeguards to ensure the confidentiality, integrity, and availability of all Protected Health Information.

---

## Record Handling and Retention

- Source uploads are deleted immediately upon completion of the summary.
- Completed summaries are retained for thirty (30) days solely to verify delivery, after which they are permanently deleted.

# Table of Contents

|                                                                |          |
|----------------------------------------------------------------|----------|
| <b><u>DISCLAIMER &amp; AGREEMENT SUMMARY</u></b>               | <b>1</b> |
| <b><u>PURPOSE AND SCOPE</u></b>                                | <b>1</b> |
| <b>PROTECTED HEALTH INFORMATION (PHI)</b>                      | <b>1</b> |
| <b>RECORD HANDLING AND RETENTION</b>                           | <b>1</b> |
| <b><u>TABLE OF CONTENTS</u></b>                                | <b>2</b> |
| <b><u>I. MEDICATION HISTORY (REFERENCE PACK)</u></b>           | <b>3</b> |
| <b>A. CURRENT LONG-TERM MEDICATIONS (AS OF SEPTEMBER 2025)</b> | <b>3</b> |
| <b>B. PREVIOUS / TRIAL MEDICATIONS</b>                         | <b>3</b> |
| <b>C. MEDICATION EFFECT AND TOLERANCE SUMMARY</b>              | <b>4</b> |
| <b>D. THERAPEUTIC NOTES</b>                                    | <b>4</b> |
| <b><u>II. PROVIDER HISTORY (REFERENCE PACK)</u></b>            | <b>5</b> |
| <b>A. TREATING AND CONSULTING PROVIDERS</b>                    | <b>5</b> |
| <b>B. PROVIDER INTERACTION SUMMARY</b>                         | <b>7</b> |
| <b><u>III. THANK YOU &amp; NEXT STEPS</u></b>                  | <b>8</b> |
| <b>A. THANK YOU</b>                                            | <b>8</b> |
| <b>C. SUPPORT &amp; CONTACT</b>                                | <b>9</b> |

# I. Medication History (Reference Pack)

(January 2021 – September 2025)

## A. Current Long-Term Medications (as of September 2025)

| Medication / Dosage                    | Indication                       | Start Date       | Status / Response                                 | Page Reference  |
|----------------------------------------|----------------------------------|------------------|---------------------------------------------------|-----------------|
| <b>Metformin 1000 mg BID</b>           | Type 2 Diabetes Mellitus         | 2018 (continued) | Maintained A1C 6.9–8.2 %; well-tolerated.         | (41, 453, 748)  |
| <b>Lisinopril 20 mg daily</b>          | Hypertension                     | 2018 (continued) | Consistent BP control (~122/74 mmHg).             | (46, 681)       |
| <b>Gabapentin 400 mg TID</b>           | Neuropathic Pain / Radiculopathy | Aug 2021         | Reduces nerve pain ~30 %; mild sedation.          | (183, 567, 720) |
| <b>Duloxetine 60 mg daily</b>          | Neuropathic Pain & Depression    | Feb 2022         | Improved mood and pain modulation (~20 % relief). | (275, 425, 720) |
| <b>Sertraline 100 mg daily</b>         | Depression / Anxiety             | Jan 2023         | Improved sleep and affect; no side effects.       | (471, 649, 865) |
| <b>Tramadol 50 mg q6h PRN</b>          | Breakthrough Pain                | May 2024         | Used intermittently; effective for flares.        | (657–672)       |
| <b>Hydrochlorothiazide 25 mg daily</b> | Adjunct for BP control           | 2020 (continued) | Maintains stable BP; no electrolyte issues.       | (52, 742)       |

## B. Previous / Trial Medications

| Medication / Dosage                          | Indication                  | Date Range          | Outcome / Reason Discontinued                          | Page Reference  |
|----------------------------------------------|-----------------------------|---------------------|--------------------------------------------------------|-----------------|
| <b>Cyclobenzaprine 5 mg TID PRN</b>          | Muscle spasm (acute injury) | May–Jul 2021        | Caused drowsiness; stopped after initial phase.        | (120–128)       |
| <b>Naproxen 500 mg BID</b>                   | Acute pain post-fall        | May–Aug 2021        | Gastrointestinal irritation; replaced with OTC NSAIDs. | (119, 150)      |
| <b>Epidural Steroid Injections (3 total)</b> | Lumbar radiculopathy        | Oct 2021 – Oct 2024 | Temporary 30–40 % relief; no lasting effect.           | (243, 269, 704) |

| Medication / Dosage               | Indication                     | Date Range     | Outcome / Reason Discontinued                  | Page Reference |
|-----------------------------------|--------------------------------|----------------|------------------------------------------------|----------------|
| Duloxetine 30 mg trial dose       | Neuropathic pain               | Jan–Feb 2022   | Dose titrated up for better response.          | (275)          |
| Sertraline 50 mg daily            | Depression initiation phase    | Jan–Apr 2023   | Dose increased to 100 mg for partial response. | (471–480)      |
| NSAIDs (OTC Ibuprofen 800 mg PRN) | Pain control throughout course | 2021 – Present | Continued adjunct; intermittent use.           | (345, 657)     |

### C. Medication Effect and Tolerance Summary

- **Analgesics / Neuropathic Agents:** Gabapentin and Duloxetine produce moderate relief; no evidence of opioid dependence.
- **Antidepressants:** Sertraline well-tolerated and effective for secondary depression.
- **Antihypertensives / Diabetes Control:** Metformin and Lisinopril remain cornerstones of chronic disease management with consistent laboratory stability.
- **Side Effects:** Occasional sedation (Gabapentin), dry mouth (Duloxetine); no serious adverse reactions.
- **Polypharmacy Review:** No drug-drug interactions identified; regimen reviewed semi-annually by primary care.

### D. Therapeutic Notes

- Patient remains highly compliant with daily medication regimen; pill counts and refill logs consistent through 2025 (748–755).
- Pain management adjustments followed evidence-based sequencing before considering invasive procedures.
- Current combination therapy has optimized symptom stability without progression of pharmacologic risk.

## II. Provider History (Reference Pack)

(January 2021 – September 2025)

### A. Treating and Consulting Providers

| Provider / Facility                                         | Specialty / Role                 | Date Range of Care   | Key Involvement / Notes                                                                                                                                         | Page Reference     |
|-------------------------------------------------------------|----------------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| <b>Dr. L. Hart, MD – Lakeside Primary Care</b>              | Primary Care / Internal Medicine | Jan 2021 – Present   | Oversaw chronic conditions (diabetes, hypertension); coordinated referrals to ortho, pain, and psych; maintained long-term medical leave documentation.         | (41–52, 681–875)   |
| <b>Dr. R. Patel, MD – Metro Orthopedics</b>                 | Orthopedic Surgery               | Sept 2021 – Jul 2025 | Evaluated post-injury back pain; performed exams, reviewed MRIs; administered first epidural; discussed but deferred surgical options.                          | (231–617, 812)     |
| <b>Dr. J. Owens, DO – Pain Management Specialists</b>       | Interventional Pain Medicine     | Jan 2022 – Aug 2025  | Managed chronic lumbar radiculopathy; performed multiple epidurals; adjusted Gabapentin / Duloxetine dosing; monitored opioid use; considered stimulator trial. | (262–275, 704–718) |
| <b>Dr. R. Lewis, MD – Endocrine Associates</b>              | Endocrinology                    | Mar 2023 – Feb 2025  | Monitored diabetes and metabolic effects of limited activity; optimized Metformin dosing; reviewed A1C trends.                                                  | (453, 748)         |
| <b>Dr. S. Nguyen, PhD / LP – Behavioral Health Services</b> | Clinical Psychology / CBT        | Feb 2023 – Oct 2025  | Provided weekly CBT; coordinated with psychiatry for medication adjustments; noted improved coping and mood stabilization.                                      | (471–498, 865)     |

| Provider / Facility                                  | Specialty / Role                   | Date Range of Care   | Key Involvement / Notes                                                                                                       | Page Reference               |
|------------------------------------------------------|------------------------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| <b>Dr. T. Miller, MD – Psychiatric Associates</b>    | Psychiatry / Medication Management | Jan 2023 – Sept 2025 | Managed antidepressant therapy (Sertraline); documented reduction in depressive symptoms; supported ongoing disability claim. | (471–498, 649–865)           |
| <b>ABC Physical Therapy Center</b>                   | Physical Therapy / Rehabilitation  | Jul 2021 – May 2024  | Conducted outpatient and aquatic therapy programs; detailed functional tolerance, pain scores, and limited improvement.       | (194–215, 628–642)           |
| <b>Metro General Hospital</b>                        | Acute Care / Emergency Department  | May 2021 & Jun 2022  | Treated initial fall injury and later chest-pain admission; provided diagnostic imaging and short-term PT assessment.         | (112–128, 301–338)           |
| <b>Advanced Imaging Center</b>                       | Radiology / Diagnostic Services    | 2021 – 2025          | Performed serial MRIs (2021, 2022, 2024, 2025); findings document degenerative progression then stabilization.                | (177, 243, 603–610, 835–840) |
| <b>ABC Pain Psychology Group</b>                     | Behavioral Pain Rehabilitation     | Oct 2022 – Dec 2024  | Provided cognitive-behavioral pain coping sessions; integrated biofeedback; noted partial improvement.                        | (392–498, 649)               |
| <b>Occupational Health &amp; Vocational Services</b> | Disability / Work Capacity Review  | 2021 – 2025          | Completed FCEs (2023, 2025); confirmed sedentary-light functional status; unable to return to prior employment.               | (505–519, 733)               |
| <b>Primary Care Nursing Team</b>                     | RN / Clinical Support              | 2021 – 2025          | Coordinated refills, vitals, and patient communication; ensured medication compliance documentation.                          | (681–755)                    |
| <b>Pharmacy Records – CVS and OptumRx</b>            | Dispensing Pharmacy                | 2021 – 2025          | Dispensed chronic medications; refill adherence consistent; no controlled-substance discrepancies.                            | (720–755)                    |

## B. Provider Interaction Summary

- **Primary coordination:** Dr. Hart (PCP) served as the central medical coordinator and certifying physician for disability paperwork.
- **Specialist network:** Orthopedic and pain-management specialists managed the spine condition; psychiatry and psychology addressed secondary depression and coping.
- **Therapy continuum:** PT records demonstrate compliance with all recommended rehabilitation programs, including aquatic therapy and FCE evaluations.
- **Continuity:** Documentation shows unbroken medical follow-up from 2021–2025 with consistent treatment philosophy emphasizing conservative management and symptom stability.



## III. Thank You & Next Steps

*(Prepared by YourMedReview LLC)*

---

### A. Thank You

Thank you for choosing **YourMedReview LLC** to organize and summarize your medical records.

Each summary is prepared through a **HIPAA-secure, AI-assisted record analysis with detailed human review**, ensuring accuracy, clarity, and consistency—so you can focus on your case, not the paperwork.

---

### B. Order or Access Another Summary

Whether you're a subscriber or ordering on demand, YourMedReview LLC makes it simple to get your next summary.

#### **Subscriber Portal**

Log in, upload new records, and request your next summary as part of your active plan. Your available summaries and delivery schedule update automatically inside the portal.

#### **One-Time Order**

Need a single case handled? Upload your files, complete secure payment, and receive a clear, attorney-ready summary—delivered on time.

Both options use the same HIPAA-secure workflow with detailed human review and guaranteed professional clarity.

Each option is HIPAA-secure, fast, and designed to fit seamlessly into your workflow.

---

## C. Support & Contact

For questions, clarification, or additional record requests, please contact:

**[support@yourmedreview.com](mailto:support@yourmedreview.com)**

**[www.yourmedreview.com](http://www.yourmedreview.com)**

---

**Prepared and Delivered by YourMedReview LLC**

Medical record summaries, made clear.

© 2025 YourMedReview LLC | All Rights Reserved